Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axcella Health (AXLA – Research Report) and Baudax Bio (BXRX – Research Report).
Axcella Health (AXLA)
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Axcella Health today and set a price target of $1.50. The company’s shares closed last Tuesday at $0.60, close to its 52-week low of $0.16.
According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of
Currently, the analyst consensus on Axcella Health is a Moderate Buy with an average price target of $2.83.
See the top stocks recommended by analysts >>
Baudax Bio (BXRX)
Noble Financial analyst Gregory Aurand maintained a Hold rating on Baudax Bio today. The company’s shares closed last Tuesday at $4.17, close to its 52-week low of $1.55.
According to TipRanks.com, Aurand is ranked #8142 out of 8294 analysts.
Baudax Bio has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AXLA:
- Axcella announces regulatory path to registration of AXA1125
- Biotech Alert: Searches spiking for these stocks today
- Axcella Health downgraded to Market Perform from Outperform at SVB Securities
- H.C. Wainwright downgrades Axcella with discontinuation ‘major detriment’
- Axcella Health downgraded to Neutral from Buy at H.C. Wainwright
